{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Salt+Lake+City&page=17&state=Utah",
    "query": {
      "state": "Utah",
      "city": "Salt Lake City",
      "page": 17
    },
    "page_size": 10
  },
  "pagination": {
    "page": 17,
    "page_size": 10,
    "total_count": 545,
    "total_pages": 55,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Salt+Lake+City&page=18&state=Utah&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Salt+Lake+City&page=16&state=Utah&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-31T07:45:48.704Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01368588",
      "title": "Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "three-dimensional conformal radiotherapy",
          "type": "RADIATION"
        },
        {
          "name": "intensity modulated radiotherapy",
          "type": "RADIATION"
        },
        {
          "name": "Brachytherapy",
          "type": "RADIATION"
        },
        {
          "name": "Anti-androgen",
          "type": "DRUG"
        },
        {
          "name": "luteinizing hormone-releasing hormone (LHRH) agonist or antagonist",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "Radiation Therapy Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 2590,
      "start_date": "2011-07",
      "completion_date": "2031-07",
      "has_results": true,
      "last_update_posted_date": "2026-05-08",
      "last_synced_at": "2026-10-31T07:45:48.704Z",
      "location_count": 454,
      "location_summary": "Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 351 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01368588"
    },
    {
      "nct_id": "NCT05486572",
      "title": "Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Carcinoma, Hepatocellular",
        "Cirrhosis"
      ],
      "interventions": [
        {
          "name": "Abbreviated Magnetic Resonance Imaging with serum AFP",
          "type": "OTHER"
        },
        {
          "name": "Abdominal Ultrasound Screening with serum AFP",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 4700,
      "start_date": "2023-11-03",
      "completion_date": "2031-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-17",
      "last_synced_at": "2026-10-31T07:45:48.704Z",
      "location_count": 34,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 31 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05486572"
    },
    {
      "nct_id": "NCT01467466",
      "title": "Prevention of Serious Adverse Events Following Angiography",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Renal Failure",
        "Kidney Disease",
        "Coronary Artery Disease"
      ],
      "interventions": [
        {
          "name": "IV isotonic saline",
          "type": "DRUG"
        },
        {
          "name": "IV isotonic bicarbonate",
          "type": "DRUG"
        },
        {
          "name": "N-acetylcysteine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5177,
      "start_date": "2013-10-07",
      "completion_date": "2017-10-17",
      "has_results": true,
      "last_update_posted_date": "2025-11-05",
      "last_synced_at": "2026-10-31T07:45:48.704Z",
      "location_count": 35,
      "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Palo Alto, California + 32 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "West Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01467466"
    },
    {
      "nct_id": "NCT06686654",
      "title": "Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Human Metapneumovirus Immunization",
        "Respiratory Syncytial Virus Immunization"
      ],
      "interventions": [
        {
          "name": "Investigational hMPV/RSV vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Investigational hMPV vaccine (monovalent)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Investigational RSV vaccine (monovalent)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Licensed RSV Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Investigational RSV+hMPV vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 1530,
      "start_date": "2024-11-11",
      "completion_date": "2027-01-18",
      "has_results": false,
      "last_update_posted_date": "2025-12-11",
      "last_synced_at": "2026-10-31T07:45:48.704Z",
      "location_count": 24,
      "location_summary": "Phoenix, Arizona • Garden Grove, California • Gardena, California + 20 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Gardena",
          "state": "California"
        },
        {
          "city": "Huntington Park",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06686654"
    },
    {
      "nct_id": "NCT06098079",
      "title": "Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Naltrexone-Bupropion (NB) Combination",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Currax Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8600,
      "start_date": "2024-01-03",
      "completion_date": "2029-07",
      "has_results": false,
      "last_update_posted_date": "2026-03-31",
      "last_synced_at": "2026-10-31T07:45:48.704Z",
      "location_count": 140,
      "location_summary": "Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 111 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06098079"
    },
    {
      "nct_id": "NCT00807768",
      "title": "Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Endometrial Clear Cell Adenocarcinoma",
        "Endometrial Serous Adenocarcinoma",
        "Fatigue",
        "Neurotoxicity Syndrome",
        "Obesity",
        "Stage I Uterine Corpus Cancer AJCC v7",
        "Stage II Uterine Corpus Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "3-Dimensional Conformal Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Intensity-Modulated Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Internal Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Gynecologic Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 601,
      "start_date": "2009-03-23",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2019-03-20",
      "last_synced_at": "2026-10-31T07:45:48.704Z",
      "location_count": 533,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 352 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00807768"
    },
    {
      "nct_id": "NCT00049335",
      "title": "S0030: Capecitabine in Treating Older Patients W/Metastatic or Recurrent Colorectal Cancer That Cannot Be Surgically Removed",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "capecitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2003-02",
      "completion_date": "2007-06",
      "has_results": false,
      "last_update_posted_date": "2013-01-03",
      "last_synced_at": "2026-10-31T07:45:48.704Z",
      "location_count": 90,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 58 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00049335"
    },
    {
      "nct_id": "NCT00002976",
      "title": "Estrogen Replacement Therapy in Treating Women With Early-Stage Endometrial Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Endometrial Cancer"
      ],
      "interventions": [
        {
          "name": "conjugated estrogens",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gynecologic Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 2108,
      "start_date": "1997-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-04-11",
      "last_synced_at": "2026-10-31T07:45:48.704Z",
      "location_count": 149,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 99 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002976"
    },
    {
      "nct_id": "NCT01322490",
      "title": "A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prostate Cancer Metastatic"
      ],
      "interventions": [
        {
          "name": "PROSTVAC-V",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PROSTVAC-F",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GM-CSF",
          "type": "DRUG"
        },
        {
          "name": "GM-CSF Placebo",
          "type": "OTHER"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Bavarian Nordic",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 1297,
      "start_date": "2011-11-28",
      "completion_date": "2017-12-15",
      "has_results": true,
      "last_update_posted_date": "2019-09-04",
      "last_synced_at": "2026-10-31T07:45:48.704Z",
      "location_count": 84,
      "location_summary": "Anchorage, Alaska • Scottsdale, Arizona • Berkeley, California + 68 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Marina del Rey",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01322490"
    },
    {
      "nct_id": "NCT05260437",
      "title": "Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "COVID-19",
        "SARS-CoV-2"
      ],
      "interventions": [
        {
          "name": "CV2CoV (2 µg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CV2CoV (4 µg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CV2CoV (8 µg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CV2CoV (12 µg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CV2CoV (16 µg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CV2CoV (20 µg)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 99,
      "start_date": "2022-03-24",
      "completion_date": "2023-03-07",
      "has_results": true,
      "last_update_posted_date": "2024-08-12",
      "last_synced_at": "2026-10-31T07:45:48.704Z",
      "location_count": 24,
      "location_summary": "Aurora, Colorado • Hallandale, Florida • Lakeland, Florida + 11 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Hallandale",
          "state": "Florida"
        },
        {
          "city": "Hallandale",
          "state": "Florida"
        },
        {
          "city": "Lakeland",
          "state": "Florida"
        },
        {
          "city": "Lakeland",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05260437"
    }
  ]
}